AstraZeneca PLC (LON:AZN)
13,674
-62 (-0.45%)
Dec 24, 2025, 2:30 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B USD in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.90
Revenue / Employee
$616.41K
Employees
94,300
Market Cap
212.05B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 787.00M | 2.40% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
| Oxford Nanopore Technologies | 204.69M |
AstraZeneca News
- 1 day ago - ABBV vs. AZN: Which Pharma Stock is the Better Investment Now? - Nasdaq
- 2 days ago - Validea Detailed Fundamental Analysis - AZN - Nasdaq
- 2 days ago - AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Benzinga
- 2 days ago - AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
- 2 days ago - AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use - Nasdaq
- 2 days ago - FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Benzinga
- 2 days ago - AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA's Breakthrough Therapy Designation In US - Nasdaq
- 2 days ago - AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals - GuruFocus